AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)
Heinz Gisslinger(Medical University of Vienna), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Michael Zoerer(AOP Orphan (Austria)), Franz-Josef Tarmann(AOP Orphan (Austria)), Ella Willenbacher(Innsbruck Medical University), Oleh Zahriychuk(AOP Orphan (Austria)), Alexander Egle(Paracelsus Medical University), Richard Greil(Paracelsus Medical University), Daniel Lechner(Medical University of Vienna), Ernst Schloegl(Hanusch Hospital), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Christoph Klade(Intercell (Austria)), Bettina Gisslinger(Medical University of Vienna), Thomas Melchardt(Paracelsus Medical University), Karin Strecker(Donauspital), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Guenther Gastl(Innsbruck Medical University), Róbert Královics(Medical University of Vienna)
Cited by 5
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Bim is a suppressor of Myc-induced mouse B cell leukemia
|Proceedings of the National Academy of Sciences|2004|482
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450